MedPath

Higher vs. Lower Doses of Steroids in Patients with COVID-19

Phase 3
Completed
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/10/028731
Lead Sponsor
Professor Anders Perner
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All the following criteria must be fulfilled:

Aged 18 years or above AND

Confirmed SARS-CoV-2(COVID-19) requiring hospitalisation AND

Use of one of the following:

Invasive mechanical ventilation OR

•Non-invasive ventilation or continuous use of continuous positive airway pressure (CPAP) for hypoxia OR

Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system

Exclusion Criteria

Use of systemic corticosteroids for other indications than COVID-19 in doses higher than 6 mg dexamethasone equivalents

Use of systemic corticosteroids for COVID-19 for 5 consecutive days or more

Invasive fungal infection

ctive tuberculosis

Fertile woman ( <60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG

Known hypersensitivity to dexamethasone

Previously randomised into the COVID STEROID 2 trial

Informed consent not obtainable

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath